Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03541369 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT03541369 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 64 participants.
The verdict
NCT03541369, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose \[RP2D\]).
Interventions
- DRUG AMG 427
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2023-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03541369
The ClinicalTrials.gov registry entry for NCT03541369 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 427 is the first listed.
NCT03541369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03541369 about?
NCT03541369 is a clinical study titled "Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia". Evaluate the safety and tolerability of AMG 427 in adult subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). Estimate the maximum tolerated dose (MTD) and / or a biologically optimal dose (eg, recommended phase 2 dose \[RP2D\]).
What is the current status of trial NCT03541369?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-09-14. Estimated completion is 2023-02-21.
What interventions are being tested in trial NCT03541369?
The interventions under investigation include: AMG 427 (DRUG).
Who is sponsoring clinical trial NCT03541369?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.